Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
March 15, 2023 10:30 ET
|
iOmx Therapeutics AG
Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platformPredictive biomarker signature for lead product candidate OMX-0407 MUNICH, Germany, March 15, 2023 ...
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 09, 2023 17:09 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling...
India Gene Editing Technology Market Databook Report 2023-2027: CRISPR, Meganucleases, TALEN, and ZFN Products, Delivery Method, Disease/Disorders, and Applications
March 03, 2023 06:58 ET
|
Research and Markets
Dublin, March 03, 2023 (GLOBE NEWSWIRE) -- The "India Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 02, 2023 07:00 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
China Gene Editing Technology Market Databook Report 2023: Business and Investment Opportunities to 2027
February 27, 2023 10:33 ET
|
Research and Markets
Dublin, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The "China Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...
Advances in Gene Editing Technologies in Healthcare, 2023 Research Report - Next-Generation Genome Editing Tools and Improved Delivery Are Bolstering Gene Editing Therapeutics and Diagnostics
February 10, 2023 10:53 ET
|
Research and Markets
Dublin, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The "Advances in Gene Editing Technologies in Healthcare" report has been added to ResearchAndMarkets.com's offering. CRISPR, ZFNs, and TALENs are...
Global CRISPR Gene Detection and Diagnostic Market Report 2023: Simultaneous Detection of Multiple Gene Targets Opens Up Huge Market Opportunities That Go Beyond Clinical Use
February 08, 2023 04:23 ET
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides. 2023...
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 01, 2023 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
CRISPR Technology Global Markets Report 2023: A $9.2 Billion Market by 2027, from $3.3 Billion in 2022
January 25, 2023 04:08 ET
|
Research and Markets
Dublin, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed exposure to the...
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:05 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...